AO/OTA Type 2R3C Distal Radius Fracture
Conditions
Brief summary
A prospective, multi-center (up to 4 sites), single-arm, study of 20 subjects. Patient enrollment will consist of subjects with an AO/OTA type 2R3C distal radius fracture. Enrollment will be prospectively stratified based on patient age (Stratum A: \<65 and Stratum B: ≥65 years)
Detailed description
The proposed study design is prospective, multi-center, single-arm, and non-randomized. RevBio is working to establish up to four (4) clinical sites. RevBio will perform site initiation visits to provide training to the investigator and its staff. Training will include information about study-specific procedures, a detailed review of the study protocol, instruction in completion of the electronic case report forms (eCRFs), informing the site about device instructions for use, and discussion of the regulatory requirements of the investigator. Patients will be recruited from the general patient population based on inclusion/exclusion criteria. Once they sign the informed consent form and complete the screening process they will be enrolled in the study and scheduled for surgery. All data will be reported to the FDA to evidence safety and efficacy and substantiate advancing to future stages in a larger expanded study.
Interventions
COMBINATION_PRODUCTAugmented with Tetranite Bone Adhesive
Participants will receive typical standard of care treatment for AO/OTA type 2R3C distal radius fractures augmented with tetranite bone adhesive.
Sponsors
RevBio
National Institute on Aging (NIA)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Unilateral, unstable and/or displaced distal radius AO/OTA type 2R3C fracture. * Standard treatment would consist of open reduction internal fixation (ORIF) with plate(s) and screws using a volar approach * Surgical visit occurs within 2 weeks of injury. * No radiographic evidence of fracture healing prior to surgical treatment. * Male or female, greater than 21 years of age * Subject living independently and ambulatory at the time of injury. * Subject, and/or subject's representatives are able and willing to provide informed consent and HIPAA authorization. * Subject able and willing to meet all study requirements, including attending all post-index procedure assessment visits and radiological tests. Intra-Operative Inclusion Criteria: * No sign of active infection at the planned operative site. * Surgeons will decide whether the fracture site is a good candidate for TN-MFF use once the site is open and they can visualize the bone and surrounding soft tissue.
Exclusion criteria
* Significant ligamentous disruption requiring independent repair * Other fractures of the carpal bones or injured limb (Note: an associated ulnar styloid fracture is not exclusionary) * Pathological fracture related to an underlying malignancy * Open fractures * A previous fracture in the injured bone within the last 12 months * Presence of other orthopaedic implant in the injured bone * Patients with presumptive diagnosis of named nerve or blood vessel injury * Current infection (either superficial or deep) at the planned operative site * Sepsis within one week from the planned index procedure * History of radiotherapy to the area * Active chemotherapy treatment * Patients receiving treatment with biologics for systemic inflammatory disease (e.g., Enbrel) * Physically or mentally compromised and unable to provide consent or perform functional examinations * Subject has a condition with anticipated survival shorter than 12 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy based on the fracture union assessment at the 26-week follow-up | 26 weeks | Fracture union assessment at the 26-week follow-up |
| Efficacy based on the DASH assessment at the 26-week timepoint | 26 weeks | DASH assessment at the 26-week timepoint |
| Safety based on the rate of serious device related adverse events | For 52 weeks following surgery | Safety based on the rate of serious device related adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient reported outcome measure: SF-36 | 2 weeks post surgery to 52 weeks post surgery | Patient reported outcome measures: SF-36 |
| Patient reported outcome measure: DASH | 2 weeks post surgery to 52 weeks post surgery | Patient reported outcome measure: DASH |
| Patient reported outcome measure: VAS Pain Score | 2 weeks post surgery to 52 weeks post surgery | Patient reported outcome measure: VAS Pain Score |
| Maintenance of reduction compared to baseline (surgery) | Surgery | Maintenance of reduction compared to baseline (surgery) |
| Grip strength compared to baseline (contralateral limb) | 6 weeks post surgery to 52 weeks post surgery | Grip strength compared to baseline (contralateral limb) |
| Fracture union assessment at the 6-,12-week follow-ups | 6-,12-week follow-ups | Fracture union assessment at the 6-,12-week follow-ups |
| Range of motion compared to baseline (contralateral limb) | 2 weeks post surgery to 52 weeks post surgery | Range of motion compared to baseline (contralateral limb) |
Contacts
CONTACTBrittany McDonough
CONTACTGracie Cleaver
STUDY_CHAIRSteven Glickel, MD
NYU Langone
Outcome results
None listed